BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Medeiros AR, Ferreira LLG, de Souza ML, de Oliveira Rezende Junior C, Espinoza-Chávez RM, Dias LC, Andricopulo AD. Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors. Biomolecules 2021;11:579. [PMID: 33920961 DOI: 10.3390/biom11040579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 da Costa APL, Silva JRA, de Molfetta FA. Computational discovery of sulfonamide derivatives as potential inhibitors of the cruzain enzyme from T. cruzi by molecular docking, molecular dynamics and MM/GBSA approaches. Molecular Simulation. [DOI: 10.1080/08927022.2022.2120625] [Reference Citation Analysis]
2 Veríssimo GC, Serafim MSM, Kronenberger T, Ferreira RS, Honorio KM, Maltarollo VG. Designing drugs when there is low data availability: one-shot learning and other approaches to face the issues of a long-term concern. Expert Opin Drug Discov 2022. [PMID: 35983695 DOI: 10.1080/17460441.2022.2114451] [Reference Citation Analysis]
3 Teles HR, Ferreira LLG, Valli M, Coelho F, Andricopulo AD. Hierarchical Clustering and Target-Independent QSAR for Antileishmanial Oxazole and Oxadiazole Derivatives. IJMS 2022;23:8898. [DOI: 10.3390/ijms23168898] [Reference Citation Analysis]
4 Xiao L, Li J, Liang Q, Liu J. Crystal structure of ( E )-(4-imidazol-1-yl-phenyl)-(2-methoxy-benzylidene)-amine monohydrate, C 17 H 17 N 3 O 2. Zeitschrift für Kristallographie - New Crystal Structures 2022;0. [DOI: 10.1515/ncrs-2022-0018] [Reference Citation Analysis]